Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Rockwell Automation — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Rockwell Automation trades at $438.29 (market cap $49.07B). The key difference: Rockwell Automation is far larger — about 10.4× Definium Therapeutics Inc. Common Shares's market cap, and Rockwell Automation pays a 1.25% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Rockwell Automation for 74 Days on average.
| DFTX | ROK | |
|---|---|---|
Market Cap | $4.71B | $49.07B |
Volume | 1,966,636 | 783,067 |
Sector | Health | Industrials |
52-Week High | $48.45 | $495.08 |
52-Week Low | $10.68 | $333.75 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $3.67B | $52.21B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rockwell Automation (ROK) trades at $434.14, down 3.68% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue for 2025 was $8.34 billion, with a net income margin of 13.38%. Recent news highlights its leadership in industrial automation and digital transformation, including partnerships in AI-enabled cyber defense.
The outlook is supported by strong profitability and analyst consensus, but high valuation multiples and competitive pressures pose risks. The consensus price target of $489.89 suggests potential upside, though investors should monitor earnings sustainability and macroeconomic factors affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
